Brenus Pharma graduates from the Creative Destruction Lab’s 2023/2024 Global Cancer Stream, in partnership with North American Universities.

Contributed by: Business Wire

Logo

Tags

Biotechnology

Health

Pharmaceutical

Clinical Trials

Oncology

Brenus Pharma

More Like This

Brenus Pharma Joins the Paris Saclay Cancer Cluster (PSCC) to Collaborate at the Heart of Innovation in Oncology

Brenus Pharma, Winner of the Call for Proposals "Innovations in Biotherapies and Bioproduction for France 2030", Receives €5 Million for Its Anticancer Vaccine Immunotherapy

Brenus Pharma Publishes Promising Proof of Concept Results of their Therapeutic Platform in the Scientific Frontiers in Oncology Journal. (1)

AACR 2024: Brenus Pharma Unveils Promising and Robust Pre-clinical Efficacy Extrapolating Human Conditions with STC-1010

Biotech Award presented to Paul Bravetti (CEO Brenus Pharma) by Thierry Hulot (President of Merck Group activities in France - President of LEEM), Alain Huriez (Chariman and Managing Partner, AdBio Partners), Guillaume LAULHE (Director BD at IQVIA) (Photo: Brenus Pharma)

Brenus Pharma Wins the "Biotech" Trophy at the Prestigious Healthtech 2024 Awards Ceremony, Organized by France Biotech

ASCO 2024: Brenus Pharma Presented “BreAK-CRC” First-in-human (FIH) Phase I/IIA Trial of STC-1010: a Next-generation Cancer Vaccine Targeting mCRC

Brenus Pharma Wins French Tech Saint-Etienne Lyon's BIG Start-up of the Year Award

Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference